China Traditional Chinese Medicine Holdings (0570) Fair Value & Analysis
Healthcare · HK · Market cap HK$6.8B
Fair value as of: Aug 13, 2026
From 11 valuation models · updated 2 days ago
Fair value updated Aug 13, 2026, revised from HK$3.18 to HK$3.19 (+0.3%) since Aug 2, 2026. Share price −6.0% over the past month.
A solid business, screening 126% undervalued on our models.
What matters now
- The price is below even our cautious bear case (HK$2.47). The market is more pessimistic than our downside scenario.
- Solid quality (57/100) at a price below fair value, the discount is the argument here, not the business quality.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range HK$1.34 – HK$6.04 · fair‑value band HK$2.47 – HK$3.90 · the HK$1.41 price screens below the HK$3.19 fair value. Dashed = 300-day average. As of Aug 13, 2026.
Analysis
China Traditional Chinese Medicine Holdings (0570) currently trades at HK$1.41, while our model-based Fair Value estimate is HK$3.19, implying the stock looks roughly 126.2% undervalued today. The Quality Score stands at 57/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, China Traditional Chinese Medicine Holdings generated revenue of HK$14.7B at a net margin of -2.3%. Revenue declined 10.4% year over year. It earns a return on equity of -2.0%. The balance sheet holds a net cash position of HK$1.6B. Fundamentals as of Aug 13, 2026
Our scenario range runs from HK$2.47 (bear case) to HK$3.90 (bull case); at HK$1.41, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 47% below its 52-week high and 7% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 126%, 0570 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 11 models by family
Widest divergence: Growth DCF (HK$9.35) versus Asset-Based (HK$2.72). Highest evidence: Growth DCF (80).
Notify me when 0570 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 58 · Market factors (momentum, volatility) 29
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally.
Full company description
China Traditional Chinese Medicine Holdings Co. Limited, an investment holding company, engages in the research and development, production, and sale of traditional Chinese medicine (TCM) and pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It operates through four segments: Yi Fang, Tian Jiang, Tong Ji Tang, and Medi-World. The company manufactures, manages, and sells concentrated TCM granules, and TCM health care products and decoction pieces, as well as TCM finished drugs. It also provides Chinese medical related healthcare solutions, including Chinese medical consultation and diagnosis, TCM physiotherapy, and prescription with concentrated TCM granules, TCM therapies, TCM decoction pieces, and TCM healthcare product through its offline medical institutions. In addition, the company is involved in the retail sale of pharmaceuticals and decoction pharmaceutical; trading of pharmaceutical products; investment of the TCM health industry; sale of medical herbs; provision of marketing, advertising and consulting of TCM; and property leasing activities. It sells its products under the Yi Fang, Tian Jiang, Tong Ji Tang, Medi-world, De Zhong, and Feng Liao Xing brands through hospitals and retail pharmacies. The company was formerly known as China Traditional Chinese Medicine Co. Limited and changed its name to China Traditional Chinese Medicine Holdings Co. Limited in 2016. China Traditional Chinese Medicine Holdings Co. Limited was founded in 1955 and is based in Wan Chai, Hong Kong.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
China Traditional Chinese Medicine Holdings reported revenue of HK$14.7B in FY2025 versus HK$19.1B in FY2021, a compound −6.2%/yr. Reported net income was −HK$342M in FY2025.
of which total revenue +17.8 pp · buybacks/dilution −4.7 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
Watch 0570: get an alert when its fair value changes →
Peer Group
Drug Manufacturers - Specialty & Generic · 624 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥53.76 | ¥25.94 | -52% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,944 | ₹989.50 | -49% |
| Divi's Laboratories Limited DIVISLAB | ₹8,500 | ₹1,932 | -77% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,915 | ₹1,163 | -76% |
| PharmaEssentia Corporation 6446 | 1,440 TWD | 233.93 TWD | -84% |
| Cipla Limited CIPLA | ₹1,463 | ₹1,001 | -32% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,167 | ₹703.32 | -40% |
| Lupin Limited LUPIN | ₹2,281 | ₹2,477 | +9% |
| Mankind Pharma Limited MANKIND | ₹2,433 | ₹983.11 | -60% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,200 | ₹874.79 | -27% |
Compare China Traditional Chinese Medicine Holdings with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is China Traditional Chinese Medicine Holdings (0570) overvalued or undervalued?
What is the fair value of 0570?
What is the quality score of 0570?
What is the revenue of China Traditional Chinese Medicine Holdings (0570)?
What is the net profit margin of 0570?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track China Traditional Chinese Medicine Holdings and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.